drugset / Trial / NCT07824986
A Phase 3 Trial in Advanced Epithelioid Mesothelioma
RandomizedParallel-groupOpen-labelTreatment
Summary
This randomized, open-label, multicenter Phase 3 trial will compare VT3989 with Investigator's choice of gemcitabine or vinorelbine in adults with advanced epithelioid pleural mesothelioma whose disease progressed after prior platinum-based systemic chemotherapy and immunotherapy.
Timeline
- Start
- 2026-12-01
- Primary completion
- 2028-05-01
- Completion
- 2031-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Subject | VT3989 | Unknown | 100 mg | Oral |
| Comparator | Vinorelbine | Small molecule | 25 mg/m2 | Intravenous |
| Comparator | Vinorelbine | Small molecule | 30 mg/m2 | Intravenous |